TY - JOUR
T1 - Present and Future Treatment of Myasthenia Gravis
AU - Drachman, Daniel B.
PY - 1987/3/19
Y1 - 1987/3/19
N2 - More than half a century ago, Mary Walker — a registrar in an obscure outlying London hospital—carried out a nonrandomized, nonblinded, uncontrolled, but highly successful trial of physostigmine in a patient with myasthenia gravis. Hailed in the press as the “Miracle of St. Alfege's Hospital,” her discovery of the beneficial effect of this anticholinesterase agent provided evidence for a defect of neuromuscular transmission in myasthenia gravis and led to the use of similar drugs in the treatment of the disease. Since that time, and particularly during the past 15 years, knowledge of the pathophysiology of myasthenia gravis and its treatment.
AB - More than half a century ago, Mary Walker — a registrar in an obscure outlying London hospital—carried out a nonrandomized, nonblinded, uncontrolled, but highly successful trial of physostigmine in a patient with myasthenia gravis. Hailed in the press as the “Miracle of St. Alfege's Hospital,” her discovery of the beneficial effect of this anticholinesterase agent provided evidence for a defect of neuromuscular transmission in myasthenia gravis and led to the use of similar drugs in the treatment of the disease. Since that time, and particularly during the past 15 years, knowledge of the pathophysiology of myasthenia gravis and its treatment.
UR - http://www.scopus.com/inward/record.url?scp=0023096436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023096436&partnerID=8YFLogxK
U2 - 10.1056/NEJM198703193161209
DO - 10.1056/NEJM198703193161209
M3 - Editorial
C2 - 3821812
AN - SCOPUS:0023096436
SN - 0028-4793
VL - 316
SP - 743
EP - 745
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 12
ER -